Moderna IncMRNA
▲ ポジティブ資本関連度
Stock surge strengthens acquisition currency and balance sheet, enabling potential M&A.
銘柄への影響 6
Biotech & Genomic Medicine
Moderna Inc
Arbutus Biopharma CorpABUS
▲ ポジティブ資本関連度
Acquisition would extinguish $1.3 billion in contingent LNP patent exposure.
Immatics NVIMTX
▲ ポジティブ資本関連度
Existing collaboration and $1.3 billion market cap make it a likely acquisition target.
Intellia Therapeutics IncNTLA
▲ ポジティブ技術関連度
Phase 3 lonvo-z shows 87% reduction in hereditary angioedema attacks, enhancing value.
Editas Medicine IncEDIT
▲ ポジティブ資本関連度
Offers cardiometabolic pipeline access, making it a strategic acquisition target.
Artificial Intelligence
